Rangering i aksjer
#42756
Midatech Pharma plc operates as a pharmaceutical company specializing in drug... Midatech Pharma plc operates as a pharmaceutical company specializing in drug delivery technologies. Its core activities revolve around the research and development of therapeutic compounds, with operations spanning the United Kingdom, broader Europe, and global markets. Currently, its pipeline includes several key developments: MTX110, an innovative direct-delivery therapy targeting diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immunosuppressant designed for topical use against psoriasis; MTD211, a sustained-release version of brexpiprazole intended for managing schizophrenia and as an add-on therapy for major depressive disorder; and MTD219, a prolonged-action formulation of tacrolimus aimed at reducing the likelihood of organ transplant rejection. Beyond its specific drug candidates, Midatech Pharma provides advanced drug delivery platforms. These include Q-Sphera, a microtechnology based on polymer microspheres that enables drugs to be released over extended periods; MidaSolve, a nanotechnology employing oligosaccharides to enhance drug solubility, allowing direct and localized administration into tumors; and MidaCore, a gold nanoparticle system engineered to precisely deliver chemotherapeutic or immunotherapeutic agents to disease sites. Established in 2000, the company maintains its headquarters in Cardiff, United Kingdom.
Aksjekurs
$0.05309195
Sist synkronisert: 2023-04-24
Handel Midatech Pharma plc (MTPH)
Antall utestående aksjer for Midatech Pharma plc (MTPH)
Antall utestående aksjer per August 2026: 0
Ifølge Midatech Pharma plc sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av August 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Midatech Pharma plc (MTPH) fra 2026 til 2026
Utestående aksjer ved utgangen av hvert år
| År |
Utestående aksjer |
Endre |
|
Ikke nok data for de angitte datoene. |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap |
Utestående aksjer |
Forskjell |
Land |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
0.00 |
-
|
BE
|
|
|
- |
-
|
KR
|